Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 Biotech Investing
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations Life Science Investing
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis Biotech Investing
Data from Incyte's TGF?R2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology Congress 2025 Biotech Investing
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' Biotech Investing
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics 2025 Biotech Investing
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 Biotech Investing
